Notoginsenoside R1 attenuates idiopathic pulmonary fibrosis through neuropilin-1/type 2 innate lymphoid cells pathway
International Immunopharmacology · 2025
DOI: 10.1016/j.intimp.2025.115385 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2025. Verfasst von Min Yang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Yunnan Key Laboratory of Sustainable Utilization of Panax notoginseng Resources, Faculty of Life Science and Technology, Kunming University of Scienc…. Hauptthemen laut MEDLINE: Ginsenosides, Idiopathic Pulmonary Fibrosis, Neuropilin-1, Lymphocytes. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung disease characterized by excessive extracellular matrix accumulation, high mortality, and limited therapeutic options. Notoginsenoside R1 (NG-R1), a major bioactive saponin derived from Panax notoginseng, possesses notable anti-inflammatory and antioxidant properties, suggesting therapeutic potential in fibrotic diseases. This study evaluated the therapeutic efficacy and underlying mechanisms of NG-R1 in a mouse model of IPF induced by bleomycin (BLM), a chemotherapeutic agent commonly used to mimic pulmonary fibrosis. Network pharmacology analysis predicted that NG-R1 primarily targets pathways related to oxidative stress and immune regulation. In a BLM-induced mouse model of IPF, NG-R1 administration significantly alleviated pulmonary fibrosis, as indicated by improved lung histopathology, reduced hydroxyproline content and collagen deposition, and enhanced antioxidant enzyme activity. Mechanistic investigations revealed that NG-R1 downregulated neuropilin-1 (NRP1) expression in group 2 innate lymphoid cells (ILC2s), key mediators of type 2 immune responses and fibrotic progression. This modulation disrupted the TGF-β1/NRP1/IL-33/stimulation expressed gene 2 (ST2) signaling axis, resulting in decreased ILC2s infiltration and reduced secretion of profibrotic cytokines IL-13 and IL-5. Collectively, these findings demonstrate that NG-R1 mitigates pulmonary fibrosis by modulating innate immune responses via the NRP1/ILC2 axis, supporting its potential as a targeted immunopharmacological therapy for IPF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Yunnan Key Laboratory of Sustainable Utilization of Panax notoginseng Resources, Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming 650500, China.
- The Third Affiliated Hospital of Yunnan University of Chinese Medicine, Kunming Municipal Hospital of Traditional Chinese Medicine, Kunming 650500, China.
- Yunnan Key Laboratory of Sustainable Utilization of Panax notoginseng Resources, Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming 650500, China; Center for Translational Rese…
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Yang, M., Fang, Y., Li, X., Yang, B., Ma, Q., Cui, X., Jiang, L., & Ge, F. (2025). Notoginsenoside R1 attenuates idiopathic pulmonary fibrosis through neuropilin-1/type 2 innate lymphoid cells pathway. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2025.115385
Vancouver
Yang M, Fang Y, Li X, Yang B, Ma Q, Cui X, et al. Notoginsenoside R1 attenuates idiopathic pulmonary fibrosis through neuropilin-1/type 2 innate lymphoid cells pathway. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2025.115385
BibTeX
@article{Yang2025,
author = {Yang, Min and Fang, Yuwen and Li, Xiaoxun and Yang, Bairong and Ma, Qiaolian and Cui, Xiuming and Jiang, Lihong and Ge, Feng},
title = {Notoginsenoside R1 attenuates idiopathic pulmonary fibrosis through neuropilin-1/type 2 innate lymphoid cells pathway},
journal = {International Immunopharmacology},
year = {2025},
doi = {10.1016/j.intimp.2025.115385}
}
EUVIMED